Symphony for camptothecins;Symphonie pour camptothécines

Bulletin du Cancer

Volumn 90, Issue 3, 2003, Pages 239-245

  Lansiaux, Amélie ^a   Bailly, Christian ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Camptothecin; Homocamptothecin; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BN 80765; BN 80927; CAMPTOTHECIN DERIVATIVE; DB 67; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; DU 144; EXATECAN; FLUOROURACIL; IRINOTECAN; KARENITECIN; KARETINECIN; LURTOTECAN; RUBITECAN; S 36272; SILATECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; MOUSE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; MUSIC; NEOPLASMS; ORGANOSILICON COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN;

EID: 0037882263     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Ettinger DS. Is there a prefered combination chemotherapy regimen for metasrastic non-small cell lung cancer? Oncologist 2002; 7: 226-33.
2. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topo-isomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002; 99: 15387-92.
3. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80: 189-216.
4. Wang JC. Cellular roles of DNA topo-isomerases: a molecular perspective. Nature Rev Mol Cell Biol 2002; 3: 430-40.
5. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topo-isomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-13.
6. Lopez-Meyer M, Nessler CL, McKnight TD. Sites of accumulation of the antitumor alkaloide camptothecin in Camptotheca acuminata. Planta Med 1994; 67: 376-8.
7. Zhou BN, Hoch JM, Johnson RK, Mattern MR, Eng WK, Ma J, et al. Use of COPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source. J Nat Prod 2000; 63: 1273-6.
8. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topo-isomerase I. J Biol Chem 1985; 260: 14873-8.
9. Burke TG, Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 1993; 212: 285-7.
10. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37: 40-6.
11. Raymond E, Campone M, Stupp R, Menten J, Chollet P, Lesimple T, et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 2002; 38: 1348-50.
12. Bedikian AY, Ellerhorst J, Smith TM, Papadopoulos N, Plager C, Eton O. Phase II trial of 9-nitro camptothecin (RFS-2000) for patients with metastatic choroidal and non-choroidal melanoma. Proc Am Ass Cancer Res 2002; 43: 2746.
13. Schoffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002; 38: 807-13.
14. Takimoto CH, Thomas R. The clinical development of 9-aminocamptothecin. Ann N Y Acad Sci 2000; 922: 224-36.
15. Vokes EE, Gordon GS, Rudin CM, Mauer AM, Watson S, Krauss S, et al. A phase II trial of 9-aminocamptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs 2001; 19: 329-33.
16. Liebes L, Hochster H, Hazarika M, Fry D, Buckley M, Phillips Z, et al. A pharmacokinetic (pk) and phase I study of intraperitoneal (ip) 9-aminocamptothecin (9-AC) treatment of tumors confined to the peritoneal cavity. Proc Am Ass Cancer Res 2002; 43: 2745.
17. Sun FX, Tohgo A, An Z, Yagi S, Hoffman RM. Camptothecin analog DX-8951f is more effective than gemcitabine against the growth and metastasis of human pancreatic cancer in orthotopic models. Proc Am Ass Cancer Res 2002; 43: 1228.
18. De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducharme M, Sakamoto N, et al. DX-8951f: summary of phase I clinical trials. Ann NY Acad Sci 2000; 922: 260-73.
19. Sharma S, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, et al. Phase I study of topo-isomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res 2002; 7: 3963-70.
20. Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002; 20: 1222-31.
21. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, et al. The novel silatecan 7-tert-buryldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000; 43: 3970-80.
22. Curran DP, Josien H, Bom D, Gabarda AE, Du W. The cascade radical annulation approach to new analogues of camptothecins. Combinatorial synthesis of silatecans and homosilatecans. Ann N Y Acad Sci 2000; 922: 112-21.
23. Pollack IE, Erff M, Bom D, Burke TG, Strode JT, Curran DP. Potent topo-isomerase I inhibition by novel silarecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 1999; 59: 4898-905.
24. Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. Therapeutic acrivity of 7-[(2-rrimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 2001; 48: 83-7.
25. Dallavalle S, Ferrari A, Biasotti B, Merlini L, Penco S, Gallo G, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 2001; 44: 3264-74.
26. Van Hattum AH, Schluper HM, Hausheer FH, Pinedo HM, Boven E. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 2002; 100: 22-9.
27. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, Hong CI. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann NY Acad Sci 2000; 922: 324-5.
28. Kim JH, Lee SK, Lim JL, Shin HJ, Hong CI. Preformulation studies of a novel camptothecin anticancer agent, CKD-602 : physicochemical characterization and hydrolytic equilibrium kinetics. Int J Pharm 2002 ; 239 : 207-11.
29. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin : inhibition of mammalian topo-isomerase I and biological activity. J Med Chem 1989 ; 32 : 715-20.
30. Nicholas AW, Wani MC, Manikumar G, Wall ME, Kohn KW, Pommier Y. Plant antitumor agents: synthesis and biological activity of ring D and ting E modified analogues of camptothecin. J Med Chem 1990 ; 33 : 972-8.
31. Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, et al. Plant antitumor agents: synthesis and structure activity of novel camptothecin analogs. J Med Chem 1993 ; 36 : 2689-700.
32. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 1998 ; 41 : 5410-9.
33. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Bigg DC. BN80245: an E-ring modified CPT with potent antiproliferative and topo-isomerase I inhibitory activities. BioOrg Med Chem 1997 ; 7 : 2235-8.
34. Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, et al. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topo-isomerase I-mediated DNA breaks. Biochemistry 1999 ; 38 : 15556-63.
35. Urasaki Y, Takebayashi Y, Pommier Y. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topo-isomerase I alterations. Cancer Res 2000 ; 60 : 6577-80.
36. Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topo-isomerase I-targeted activity and antitumor properties. Cancer Res 1999 ; 59 : 2939-43.
37. Chauvier D, Chourpa I, Bigg DC, Manfait M. Kinetics of in vitro hydrolysis of homocamptothecins as measured by fluorescence. Ann NY Acad Sci 2000 ; 922 : 314-6.
38. Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, et al. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem 2000 ; 43 : 2285-9.
39. Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, et al. The homocamptothecin BN 80915 is a highly potent otally active topo-isomerase I poison. Anticancer Drugs 2001 ; 12 : 9-19.
40. Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 2001 ; 61 : 2961-7.
41. Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckatt Y, Gotdover L, et al. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than orhet topo-isomerase I inhibirors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 2000 ; 6 : 1557-62.
42. Lansiaux A, Facompre M, Wattez N, Hildebrand MP, Bal C, Demarquay D, et al. Apoptosis induced by the homocamptothecin anricancer drug BN80915 in HL-60 cells. Mol Pharmacol 2001 ; 60 : 450-61.
43. Chauvier D, Morjani H, Manfait M. Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells. Int J Oncol 2002b ; 20 : 855-63.
44. Kasprzyk PG, Carlson M, Lauer J, Savola A, Meshaw KM, Alford TL, et al. Antitumor activity of orally administered BN80915, a novel topo-isomerase I inhibitor, in xenograft models. Proc Am Ass Cancer Res 2000 ; 41 : 5201.
45. Bonneterre J, Cottu P, Adenis A, Bonneterre ME, Obach R, Principe P, et al. Phase I trial of BN80915 administered intravenously in patients with advanced malignant tumors. Ann Oncol 2000 ; 11 : 234.
46. Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, et al. BN 80927 : a novel homocamptothecin with inhibitory activities on both topo-isomerase I and topo-isomerase II. BioOrg Med Chem Lett 1999 ; 9 : 2599-602.
47. Demarquay D, Coulomb H, Huchet M, Lesueut-Ginot L, Camara J, Lavergne O, et al. The homocamptothecin, BN 80927, is a potent topo-isomerase I poison and topo-isomerase II catalytic inhibitor. Ann NY Acad Sci 2000 ; 922 : 301-2.
48. Huchet M, Demarquay D, Coulomb H, Kasprzyk P, Carlson M, Lauer J, et al. The dual topo-isomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann NY Acad Sci 2000 ; 922 : 303-5.
49. Lansiaux A, Hildebrand MP, Bal C, Wattez N, Demarquay D, Huchet M, et al. DNA macroarrays to identify genes responsive to apoptosis induced by the homocamptothecins BN80915 and BN80927. Proc Am Ass Cancer Res 2002 ; 43 : 5380.
50. Du W, Curran DP, Bevins RL, Zimmer SG, Zhang J, Burke TG. Synthesis and evaluation of a novel E-ring modified alpha-hydroxy keto ethet analogue of camptothecin. BioOrg Med Chem 2002 ; 10 : 103-10.
51. I. Lavielle G, Hautefaye P, Pierré A, Atassi G, Hickman J, Cimetière B. Camptothecin analogues, processes for their preparation and pharmaceutical compositions containing them. EP 1101765 A2, ADIR ET CO, 2001.
52. Hautefaye P, Cimetière B, Pierté A, Hickman J, Bailly C, Lavielle G. Synthesis and pharmacological evaluation of novel E-ring non-lactone analogues of camptothecin. Poster meeting in Barcelona, Spain, September 2002.